Qureight is an end-to-end imaging CRO company on a mission to accelerate clinical trials. We provide enterprise-grade imaging and precision endpoints for the biopharmaceutical industry. Our AI-powered data and imaging curation platform permits the analysis of clinical imaging and other healthcare data from patients with lung and heart disease, helping our customers bring treatments to market, faster. We provide automated image management and AI analysis in therapeutic areas such as Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Bronchiectasis, and Pulmonary Hypertension. Our world-leading team of scientists, engineers and clinicians is based in Cambridge, UK.
Qureight
- Life Sciences
- Cambridge, United Kingdom
- £15m
- qureight.com
- Update Information
More venture news
- 18 Sept 2026

Big Picture BioBig Picture Bio raises a £1.5m pre-seed round led by Kadmos Capital and Exceptional Ventures to design cancer combination therapies
Pre-seedLife Sciences - 16 Sept 2026

Eterna RegenerativesEterna Regeneratives closes a seed round led by Hoxton Ventures and The Venture Collective to develop keratin-based enamel repair
SeedLife Sciences - 15 Sept 2026

Magnitude BiosciencesMagnitude Biosciences raises £1.3m led by Northstar Ventures to run drug discovery screens in living nematode worms
EquityLife Sciences
